United States: WilmerHale Reps Vtesse Inc. In Acquisition By Sucampo
Last Updated: April 7 2017

Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, and Vtesse Inc., a privately held rare disease company, announced that Sucampo has acquired Vtesse for upfront consideration of $200 million. Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand; no external financing was utilized.

Steven Singer and Gary Schall led WilmerHale's representation of Vtesse in this transaction, with a team that included Steven Barrett, William Caporizzo, Jeffrey Hermanson, Scott Kilgore, David Sluis, Libby Ragan, Ben Kelsey and Alan Wilson.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Alan Wilson, Jonathan Wolfman
By Ambassador Charlene Barshefsky, Naboth van den Broek, David Ross, Patrick J. McLain, David Horn
By Frederick Saugman
By Bill Warren
By Michael Connor, H. David Gold, Sarah Judkins, Andrew L. Spielman
By Lester Ross, Tingting Liu
By H. David Gold, Rachel Jacobson, Heidi K. Ruckriegle
By Joseph Mueller, Thomas Saunders, Leslie Pearlson
By WilmerHale
By Robert D. Burke, A. William Caporizzo, Julie Hogan Rodgers, Meghan Walsh
Font Size: